ESTRO 2024 - Abstract Book

S2426

Clinical - Urology

ESTRO 2024

4. Del Ben F, Turetta M, Celetti G, et al. A Method for Detecting Circulating Tumor Cells Based on the Measurement of Single-Cell Metabolism in Droplet-Based Microfluidics. Angew Chem Int Ed Engl. 2016;55:8581 – 8584.

1359

Poster Discussion

Individual patient data analysis of salvage radiotherapy trials: RTOG 0534 and GETUG-AFU 16

Osama Mohamad 1 , Stephanie Pugh 2 , Pascal Pommier 3 , Alan Pollack 4 , Himanshu R Lukka 5 , Robert Rutledge 6 , Andre Guy Martin 7 , Shyamal Patel 8 , David Sarin 9 , Alexander G Balogh 10 , Jeff M Michalski 11 , Peter Vavassis 12 , Stéphane Guerif 13 , Stephane Supiot 14 , Igor Latorzeff 15 , Sylvie Chabaud 16 , Meryem Brihoum 16 , Jessica Lyness 2 , Howard Sandler 17 , Paul Sargos 18 , Felix Y Feng 19 1 MD Anderson Cancer Center, Radiation Oncology, Houston, USA. 2 NRG, NRG, Philadelphia, USA. 3 Centre Léon Bérard, Radiation Oncology, Lyon, France. 4 University of Miami, Radiation Oncology, Miami, USA. 5 McMaster University, Oncology, Hamilton, Canada. 6 Nova Scotia Cancer Centre, Radiation Oncology, Nova Scotia, Canada. 7 Hotel-Dieu de Quebec-Université Laval, Radiation Oncology, Québec, Canada. 8 Saint Joseph's Hospital and Medical Center, Radiation Oncology, Phoenix, USA. 9 Tel-Aviv Sourasky Medical Center, Radiation Oncology, Tel Aviv, Israel. 10 Tom Baker Cancer Centre, Radiation Oncology, Calgary, Canada. 11 Washington University at St Louis, Radiation Oncology, St Louis, USA. 12 CIUSSSEMTL-Hopital Maisonneuve-Rosemont, Radiation Oncology, Montreal, Canada. 13 CHU de Poitiers, Radiation Oncology, Poitiers, France. 14 University of Nantes, Radiation Oncology, Nantes, France. 15 La Clinique Pasteur, Radiation Oncology, Toulouse, France. 16 Unicancer, Unicancer, Lyon, France. 17 Cedars-Sinai Medical Center, Radiation Oncology, Los Angeles, USA. 18 Insitut Bergonié, Radiation Oncology, Bordeaux, France. 19 University of California San Francisco, Radiation Oncology, San francisco, USA

Purpose/Objective:

A secondary analysis of NRG/RTOG 9601 suggested that the benefit seen with long-term hormone therapy (2 years of bicalutamide 150 mg) is limited to patients treated at pre-salvage radiotherapy (SRT) PSA of >0.6 ng/ml. This individual patient data pooled analysis of relevant trials aimed to investigate the benefit of short-term (6 months) androgen deprivation therapy (STADT) with SRT and whether benefit of STADT differs by pre-specified subgroups.

Material/Methods:

We performed a systematic literature search in MEDLINE (PubMed), Embase, and clinicaltrials.gov to identify phase III randomized trials published between Jan 1, 1980, and Dec 30, 2022. Trials were included if they were fully published in English and evaluated the addition of STADT in men receiving SRT for recurrent prostate cancer after radical prostatectomy. The primary outcomes were metastasis-free survival (MFS) and overall survival (OS) which were estimated using the Kaplan-Meier method and between group tests conducted using the log-rank test. Hazard ratios were obtained using Cox proportional hazards models. Adjustment was made for treatment group, entry level PSA (cut off 0.3), Gleason score, seminal vesicle involvement (SVI), margin status (positive vs. negative), age (<65 vs. ≥ 65), ECOG performance status (PS), time from radical prostatectomy (RP) to RT start, and